Speaking of information access, consider the challenges of organizing content faced by microarray database designers. First, the amount of information on microarrays can be enormous. Second, each ...
CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in ...
H3 will use Compendia’s Oncomine tools, and companies will mine The Cancer Genome Atlas. Compendia Bioscience and H3 Biomedicine are joining forces to leverage genomics in the development of cancer ...
Thermo Fisher Scientific Inc. TMO recently announced the receipt of the FDA premarket approval (PMA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify epidermal growth ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Sensitizing K-Ras G12D mutant colorectal patient-derived organoids via ferroptosis pathway. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...
Prof. Hofman will present results of a multi-centric study evaluating performance of new Oncomine Dx Express Test, CE IVD for genomic profiling of cancer patient samples. The data cover performance ...
Thermo Fisher Scientific, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results